About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Genetic Mutation Increases Risk of Death for Thyroid Cancer Patients

by Sheela Philomena on April 11, 2013 at 9:31 AM
Font : A-A+

 Genetic Mutation Increases Risk of Death for Thyroid Cancer Patients

BRAF V600E genetic mutation is associated with a higher cancer-related death among patients with papillary thyroid cancer (PTC), finds study published in JAMA.

"Papillary thyroid cancer is the most common endocrine malignancy and accounts for 85 percent to 90 percent of all thyroid cancers," according to background information in the article. "The overall 5-year patient survival rate for PTC is 95 percent to 97 percent. A major clinical challenge is how to reliably distinguish patients who need aggressive treatments to reduce mortality from those who do not. This represents a widely controversial issue in thyroid cancer medicine, particularly because of the low overall mortality of this cancer. The issue has become even more challenging given the high annual incidence of PTC." BRAF V600E is a prominent oncogene [ a gene, one or more forms of which is associated with cancer] in PTC and "has drawn considerable attention as a potential prognostic factor for PTC. However, the clinical significance of this mutation in PTC-related mortality has not been established."

Advertisement

Mingzhao Xing, M.D., Ph.D., of the Johns Hopkins University School of Medicine, Baltimore, and colleagues conducted a study to examine and define the association between the BRAF V600E mutation and PTC-related mortality. The study included 1,849 patients (1,411 women and 438 men) with a median (midpoint) age of 46 years and an overall median follow-up time of 33 months after initial treatment at 13 centers in 7 countries between 1978 and 2011.

The overall prevalence of BRAF V600E was 45.7 percent (845/1,849). There were 56 PTC-related deaths among the 1,849 patients, representing an overall mortality of 3.0 percent. Among these deaths, 45 cases (80.4 percent) were positive for BRAF V600E. The overall mortality of all PTC cases was 5.3 percent (45/845) in BRAF V600E-positive patients vs. 1.1 percent (11/1,004) in mutation-negative patients.
Advertisement

When the aggressive tumor features of lymph node metastasis, extrathyroidal invasion, and distant metastasis were also included in the model, the association of BRAF V600E with mortality for all PTC was no longer significant, the authors write. "A higher BRAF V600E-associated patient mortality was also observed in several clinicopathological subcategories, but statistical significance was lost with adjustment for patient age, sex, and medical center."

"In summary, in this multicenter study, the presence of the BRAF V600E mutation was significantly associated with increased cancer-related mortality among patients with PTC. However, overall mortality in PTC is low, and the association was not independent of tumor behaviors. Therefore, how to use BRAF V600E for the management of mortality risk among patients with PTC is not clear. These findings support further investigation of the prognostic and therapeutic implications of BRAF V600E status in PTC."

Source: Newswise
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
International Day of Persons with Disabilities 2021 - Fighting for Rights in the Post-COVID Era
Effect of Blood Group Type on COVID-19 Risk and Severity
Woman with Rare Spinal Cord Defect from Birth Sues Doctor
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Iodine Deficiency Disorder Hyperthyroidism Hypothyroidism Cancer and Homeopathy Genetics and Stem Cells Cancer Facts Death Facts Genetic Testing of Diseases Cancer Tattoos A Body Art 

Recommended Reading
Thyroid Cancer
"Shaped like a butterfly she sits within the neck," that's what an anonymous poet wrote about the .....
Quiz on Thyroid
Feeling tired or depressed is a common enough complaint, particularly among women. Paying attention ...
Radioiodine Resistance in Some Advanced Thyroid Cancers Reversed By Drug
According to new research, the experimental drug selumetinib may allow some patients with advanced ....
FDA Approves New Drug for Rare Thyroid Cancer
The U.S. Food and Drug Administration (FDA) has approved a new drug called Cometriq to treat a rare ...
Genetic Testing of Diseases
Genetic testing helps to confirm a genetic condition in an individual and involves q complex laborat...
Hyperthyroidism
Hyperthyroidism is a condition in which the thyroid gland makes excessive thyroid hormone. Grave’s d...
Hypothyroidism
Symptoms of hypothyroidism are often general, unspecific changes in the body. Lethargy, weight gain,...
Iodine Deficiency Disorder
To control IDD, the ‘National Goiter Control Program (NGCP)’ was launched which was later renamed as...
Tattoos A Body Art
Tattoos are a rage among college students who sport it for the ‘cool dude’ or ‘cool babe’ look...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use